Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study
- Authors
- Kim, Sun Hwa; Kim, Sin Gon; Kim, Doo Man; Woo, Jeong-Taek; Jang, Hak Chul; Chung, Choon Hee; Ko, Kyung Soo; Park, Jeong Hyun; Park, Yong Soo; Kim, Sang Jin; Choi, Dong Seop
- Issue Date
- 12월-2015
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Lobeglitazone; Thiazolidinediones; Clinical trial; Randomised trial
- Citation
- DIABETES RESEARCH AND CLINICAL PRACTICE, v.110, no.3, pp.E27 - E30
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIABETES RESEARCH AND CLINICAL PRACTICE
- Volume
- 110
- Number
- 3
- Start Page
- E27
- End Page
- E30
- ISSN
- 0168-8227
- Abstract
- We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.